AstraZeneca at a glance

“Closing the year with another strong quarter, our performance confirmed that AstraZeneca has returned to growth. Our new medicines performed particularly well across the therapy areas and the Emerging Markets business went from strength to strength. 2019 will be a year of focus on continued pipeline delivery and flawless commercial execution. The performance of our new medicines demonstrated the ability of our commercial teams to convert the pipeline into successful medicines.”

Pascal Soriot
Chief Executive Officer

A science-led, innovation strategy
Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

Achieve Scientific Leadership
A focus on innovative science in three main therapy areas and a sustainable R&D model that supports our growing pipeline.

Return to Growth
Driving towards a greater presence in speciality-care medicines in balance with primary care.

Be a Great Place to Work
A culture that promotes scientific curiosity, is agile and high-performing, and which attracts, develops and retains great people.

2018 financial highlights

<table>
<thead>
<tr>
<th>Year</th>
<th>Product Sales (m)</th>
<th>Core Operating Profit (m)</th>
<th>Core Earnings per Share (EPS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>$21,049</td>
<td>$5,672</td>
<td>$3.46</td>
</tr>
<tr>
<td>2017</td>
<td>$20,152</td>
<td>$6,855</td>
<td>$4.28</td>
</tr>
<tr>
<td>2016</td>
<td>$21,319</td>
<td>$6,721</td>
<td>$4.31</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Reported EBITDA (m)</th>
<th>Net Cash Flow from Operating Activities (m)</th>
<th>Dividend per Ordinary Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>$7,140</td>
<td>$2,618</td>
<td>$2.80</td>
</tr>
<tr>
<td>2017</td>
<td>$6,713</td>
<td>$3,578</td>
<td>$2.80</td>
</tr>
<tr>
<td>2016</td>
<td>$7,259</td>
<td>$4,145</td>
<td>$2.80</td>
</tr>
</tbody>
</table>

Distinctive R&D capabilities
Small molecule and biologic medicines, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science.

Strategic R&D Centre and Global Headquarters
Cambridge, UK

Strategic R&D Centre
Gothenburg, Sweden

Strategic R&D Centre
Gaithersburg, US

LSE, STO, NYSE: AZN
astrazeneca.com/investors
Broad R&D platform in three therapy areas

Oncology
Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations. We seek to achieve this by means of our combination-focused pipeline that exploits the power of four scientific platforms.

2018: 49%
growth at CER

Cardiovascular, Renal and Metabolism (CVRM)
We push the boundaries of science to transform how cardiovascular and metabolic diseases are understood, interact and impact one another.

2018: (8%)
growth at CER

Respiratory
We aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologic medicines along with scientific research targeting disease modification.

2018: 3%
growth at CER

Global commercial presence, with strength in Emerging Markets

Emerging Markets (m)
2018: $6,891
2017: $6,149
2016: $5,794

In 2018, sales increased by 11%, reflecting strong launch trajectories of new Oncology medicines such as Tagrisso and Imfinzi and also Fasenra in Respiratory.

US (m)
2018: $6,876
2017: $6,169
2016: $7,365

Solid performances in 2018 by New Medicines, which represented 28% of sales (up from 18% in 2017). Overall sales were impacted by competitive and pricing pressures for Symbicort and early generic entry for Crestor, resulting in a decline of 6% (10% at CER).

Europe (m)
2018: $4,459
2017: $4,753
2016: $5,064

2018 sales growth declined by 8% (9% by CER). New Medicines in this region represented 24% of sales, up from 13% in 2017. Japan sales in the year declined by 9% (11% at CER) due to the impact of generic Crestor and biennial price reductions.

Established Rest of World (m)
2018: $2,823
2017: $3,081
2016: $3,096

Our talented colleagues

We’re committed to achieving our Purpose in a sustainable way and upholding our Values by fostering a strong AstraZeneca culture.

Colleagues
64,600
2017: 61,100
2016: 59,700

Note: All numbers from 2018 unless stated otherwise.